{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:56:52Z","timestamp":1787615812112,"version":"build-2736575974"},"reference-count":106,"publisher":"Elsevier BV","issue":"5-6","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1053\/j.seminoncol.2018.10.001","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T18:49:14Z","timestamp":1540925354000},"page":"303-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Current therapeutic options in metastatic castration-resistant prostate cancer"],"prefix":"10.1053","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4380-6947","authenticated-orcid":false,"given":"Gianluca","family":"Ingrosso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Detti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Scartoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6106-7725","authenticated-orcid":false,"given":"Andrea","family":"Lancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Baki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Carta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Livi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2018.10.001_bib0001","series-title":"1999\u20132013 Incidence and Mortality Web-based Report. [Internet]. Atlanta: U.S. Department of Health and Human Services","year":"2016"},{"issue":"4","key":"10.1053\/j.seminoncol.2018.10.001_bib0002","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"issue":"10","key":"10.1053\/j.seminoncol.2018.10.001_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139440","article-title":"Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model","volume":"10","author":"Scher","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1053\/j.seminoncol.2018.10.001_bib0004","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","article-title":"Hormonal impact of the 17alpha-hydroxylase\/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer","volume":"90","author":"O'Donnell","year":"2004","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1053\/j.seminoncol.2018.10.001_bib0005","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","article-title":"Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy","volume":"28","author":"Ryan","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminoncol.2018.10.001_bib0006","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s40262-016-0403-6","article-title":"Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide","volume":"55","author":"Benoist","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"21","key":"10.1053\/j.seminoncol.2018.10.001_bib0007","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Arbiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"De Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.seminoncol.2018.10.001_bib0008","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1053\/j.seminoncol.2018.10.001_bib0009","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","article-title":"Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised tri","volume":"13","author":"Logothetis","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.10.001_bib0010","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.10.001_bib0011","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1053\/j.seminoncol.2018.10.001_bib0012","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1470-2045(13)70424-8","article-title":"Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial","volume":"14","author":"Basch","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2018.10.001_bib0013","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2016.02.035","article-title":"Low Incidence of corticosteroid-associated adverse events on long-term exposure to low-dose prednisone given with abiraterone acetate to patients with metastatic castration-resistant prostate cancer","volume":"70","author":"Fizazi","year":"2016","journal-title":"Eur Urol"},{"issue":"13","key":"10.1053\/j.seminoncol.2018.10.001_bib0014","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.10.001_bib0015","unstructured":"EMA. CMHP Report - Xtandi [Internet]. 2013. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002639\/WC500144998.pdf"},{"key":"10.1053\/j.seminoncol.2018.10.001_bib0016","unstructured":"US FDA. Clinical pharmacology and biopharmaceutics review(S)\u202f: Xtandi [Internet]. 2012. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203415Orig1s000ClinPharmR.pdf"},{"issue":"11","key":"10.1053\/j.seminoncol.2018.10.001_bib0017","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1586\/14737140.2014.965686","article-title":"Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view","volume":"14","author":"Bracarda","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.10.001_bib0018","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/annonc\/mdt571","article-title":"Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial","volume":"25","author":"Sternberg","year":"2014","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1053\/j.seminoncol.2018.10.001_bib0019","series-title":"American Society of Clinical Oncology Genitourinary Cancers Symposium","article-title":"Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: baseline characteristics and efficacy outcomes","author":"Fleming","year":"2013"},{"issue":"5","key":"10.1053\/j.seminoncol.2018.10.001_bib0020","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminoncol.2018.10.001_bib0021","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2016.03.017","article-title":"The PREVAIL study: primary outcomes by site and extent of baseline disease for enzalutamide-treated men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer","volume":"70","author":"Evans","year":"2016","journal-title":"Eur Urol"},{"issue":"5","key":"10.1053\/j.seminoncol.2018.10.001_bib0022","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(15)70113-0","article-title":"Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised","volume":"16","author":"Loriot","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.10.001_bib0023","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.juro.2015.06.106","article-title":"Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies","volume":"194","author":"Crawford","year":"2015","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2018.10.001_bib0024","doi-asserted-by":"crossref","unstructured":"Zhang W., Wu T.-Y., Chen Q., et al. Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review. Asian J Androl. 19(2):196-202. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27212123","DOI":"10.4103\/1008-682X.178483"},{"issue":"3","key":"10.1053\/j.seminoncol.2018.10.001_bib0025","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ecl.2011.05.004","article-title":"Management of side effects of androgen deprivation therapy","volume":"40","author":"Grossmann","year":"2011","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"14","key":"10.1053\/j.seminoncol.2018.10.001_bib0026","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.ejca.2015.06.106","article-title":"The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer","volume":"51","author":"Iacovelli","year":"2015","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1053\/j.seminoncol.2018.10.001_bib0027","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/pros.21263","article-title":"Drug safety is a barrier to the discovery and development of new androgen receptor antagonists","volume":"71","author":"Foster","year":"2011","journal-title":"Prostate"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.10.001_bib0028","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/pcan.2013.41","article-title":"Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer","volume":"17","author":"Goodman","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1053\/j.seminoncol.2018.10.001_bib0029","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1517\/14656566.2015.995090","article-title":"Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer","volume":"16","author":"Zhang","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"10.1053\/j.seminoncol.2018.10.001_bib0030","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminoncol.2018.10.001_bib0031","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","article-title":"A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509","volume":"3","author":"Joseph","year":"2013","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1053\/j.seminoncol.2018.10.001_bib0032","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","article-title":"An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)","volume":"3","author":"Korpal","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1053\/j.seminoncol.2018.10.001_bib0033","doi-asserted-by":"crossref","first-page":"e00499","DOI":"10.7554\/eLife.00499","article-title":"Overcoming mutation-based resistance to antiandrogens with rational drug design","volume":"2","author":"Balbas","year":"2013","journal-title":"Elife"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.10.001_bib0034","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.10.001_bib0035","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1053\/j.seminoncol.2018.10.001_bib0036","doi-asserted-by":"crossref","first-page":"719","DOI":"10.6004\/jnccn.2014.0073","article-title":"Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes","volume":"12","author":"Aggarwal","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.10.001_bib0037","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1053\/j.seminoncol.2018.10.001_bib0038","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdt136","article-title":"Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)","volume":"24","author":"Loriot","year":"2013","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"7","key":"10.1053\/j.seminoncol.2018.10.001_bib0039","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/annonc\/mdt138","article-title":"Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide","volume":"24","author":"Noonan","year":"2013","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.10.001_bib0040","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.eururo.2013.06.042","article-title":"Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone","volume":"65","author":"Schrader","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.10.001_bib0041","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2013.08.020","article-title":"Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone","volume":"50","author":"Bianchini","year":"2014","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1053\/j.seminoncol.2018.10.001_bib0042","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/pros.22844","article-title":"Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone","volume":"74","author":"Suzman","year":"2014","journal-title":"Prostate"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.10.001_bib0043","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eururo.2014.06.045","article-title":"Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients","volume":"67","author":"Azad","year":"2015","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2018.10.001_bib0044","series-title":"ASCO annual meeting","first-page":"e16031","article-title":"Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate cancer (mCRPC)","author":"Zhang","year":"2014"},{"key":"10.1053\/j.seminoncol.2018.10.001_bib0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0093-7754(01)90148-4","article-title":"Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer","volume":"28","author":"Pienta","year":"2001","journal-title":"Semin Onc"},{"key":"10.1053\/j.seminoncol.2018.10.001_bib0046","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.1158\/0008-5472.CAN-10-0585","article-title":"Kyprianou N Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer","volume":"70","author":"Zhu","year":"2010","journal-title":"Cancer Res"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.10.001_bib0047","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.eururo.2013.07.022","article-title":"Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer","volume":"65","author":"Fitzpatrick","year":"2014","journal-title":"Eur Urol"},{"issue":"3","key":"10.1053\/j.seminoncol.2018.10.001_bib0048","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00003088-200645030-00002","article-title":"Clinical pharmacokinetics of docetaxel\u202f: recent developments","volume":"45","author":"Baker","year":"2006","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.10.001_bib0049","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1053\/j.seminoncol.2018.10.001_bib0050","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","article-title":"Randomized, double-blind, controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain","volume":"21","author":"Ernst","year":"2003","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1053\/j.seminoncol.2018.10.001_bib0051","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1053\/j.seminoncol.2018.10.001_bib0052","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.10.001_bib0053","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.10.001_bib0054","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(12)70537-5","article-title":"2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial","volume":"14","author":"Kellokumpu-Lehtinen","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2018.10.001_bib0055","series-title":"Analogue-Based Drug Discovery III","first-page":"319","article-title":"Novel taxanes: cabazitaxel case study","author":"Bouchard","year":"2013"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.10.001_bib0056","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/1078-0432.CCR-08-0596","article-title":"Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors","volume":"15","author":"Mita","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1053\/j.seminoncol.2018.10.001_bib0057","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1053\/j.seminoncol.2018.10.001_bib0058","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1634\/theoncologist.2011-0364","article-title":"The European Medicines Agency review of cabazitaxel (Jevtana\u00ae) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use","volume":"17","author":"Pean","year":"2012","journal-title":"Oncologist"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.10.001_bib0059","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40273-013-0050-9","article-title":"Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal","volume":"31","author":"Kearns","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"10.1053\/j.seminoncol.2018.10.001_bib0060","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2147\/DDDT.S64940","article-title":"Preclinical profile of cabazitaxel","volume":"8","author":"Vrignaud","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"10.1053\/j.seminoncol.2018.10.001_bib0061","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2217\/fon.11.23","article-title":"TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer","volume":"7","author":"Oudard","year":"2011","journal-title":"Future Oncol"},{"key":"10.1053\/j.seminoncol.2018.10.001_bib0062","first-page":"117","article-title":"Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer","volume":"5","author":"Paller","year":"2011","journal-title":"Drug Des Devel Ther"},{"issue":"22","key":"10.1053\/j.seminoncol.2018.10.001_bib0063","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1200\/JCO.2006.06.1044","article-title":"Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)","volume":"24","author":"Kudoh","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminoncol.2018.10.001_bib0064","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1200\/JCO.2004.08.048","article-title":"Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342","volume":"22","author":"Winer","year":"2004","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminoncol.2018.10.001_bib0065","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1586\/era.12.88","article-title":"Cabazitaxel in metastatic castration-resistant prostate cancer","volume":"12","author":"Yap","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"issue":"9","key":"10.1053\/j.seminoncol.2018.10.001_bib0066","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdn171","article-title":"A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients","volume":"19","author":"Pivot","year":"2008","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"9747","key":"10.1053\/j.seminoncol.2018.10.001_bib0067","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial","volume":"376","author":"De Bono","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.1053\/j.seminoncol.2018.10.001_bib0068","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1093\/annonc\/mdt194","article-title":"Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial","volume":"24","author":"Bahl","year":"2013","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1053\/j.seminoncol.2018.10.001_bib0069","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","article-title":"Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m2) and the currently approved dose (25 mg\/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer - PROSELICA","volume":"35","author":"Eisenberger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1053\/j.seminoncol.2018.10.001_bib0070","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial\u2014FIRSTANA","volume":"35","author":"Oudard","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2018.10.001_bib0071","unstructured":"US FDA. PROVENGE (Sipuleucel-T) [Internet]. 2010. Available from https:\/\/www.fda.gov\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/ucm210012.htm"},{"key":"10.1053\/j.seminoncol.2018.10.001_bib0072","unstructured":"NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) - Prostate Cancer - Version 2.2017. 2017;"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.10.001_bib0073","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1345\/aph.1K429","article-title":"Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer","volume":"42","author":"Patel","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"19","key":"10.1053\/j.seminoncol.2018.10.001_bib0074","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1053\/j.seminoncol.2018.10.001_bib0075","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/cncr.24429","article-title":"Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer","volume":"115","author":"Higano","year":"2009","journal-title":"Cancer"},{"issue":"5","key":"10.1053\/j.seminoncol.2018.10.001_bib0076","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminoncol.2018.10.001_bib0077","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jnci\/djr514","article-title":"Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer","volume":"104","author":"Huber","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.10.001_bib0078","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.urology.2013.01.061","article-title":"Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial","volume":"81","author":"Schellhammer","year":"2013","journal-title":"Urology"},{"issue":"3","key":"10.1053\/j.seminoncol.2018.10.001_bib0079","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/pcan.2014.21","article-title":"Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T","volume":"17","author":"Small","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1053\/j.seminoncol.2018.10.001_bib0080","first-page":"122","article-title":"The rationale for optimal combination therapy with sipuleucel-T for patients with castration-resistant prostate cancer","volume":"16","author":"Mouraviev","year":"2014","journal-title":"Rev Urol"},{"key":"10.1053\/j.seminoncol.2018.10.001_bib0081","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","article-title":"Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007)","volume":"184","author":"N\u00f8rgaard","year":"2010","journal-title":"J Urol"},{"issue":"Suppl 7","key":"10.1053\/j.seminoncol.2018.10.001_bib0082","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2009.0080","article-title":"The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors","volume":"7","author":"Lipton","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"16","key":"10.1053\/j.seminoncol.2018.10.001_bib0083","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.seminoncol.2018.10.001_bib0084","first-page":"3120","article-title":"Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model","volume":"62","author":"Henriksen","year":"2002","journal-title":"Cancer Res"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.10.001_bib0085","first-page":"252","article-title":"Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice","volume":"44","author":"Henriksen","year":"2003","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1053\/j.seminoncol.2018.10.001_bib0086","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s00259-013-2427-6","article-title":"Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer","volume":"40","author":"Carrasquillo","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1053\/j.seminoncol.2018.10.001_bib0087","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1517\/14656566.7.11.1475","article-title":"Samarium for osteoblastic bone metastases and osteosarcoma","volume":"7","author":"Anderson","year":"2006","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"10.1053\/j.seminoncol.2018.10.001_bib0088","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.2967\/jnumed.115.157123","article-title":"A Phase 1, open-label study of the biodistribution, pharmacokinetics, and dosimetry of 223RA-dichloride in patients with hormone-refractory prostate cancer and skeletal metastases","volume":"56","author":"Chittenden","year":"2015","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1053\/j.seminoncol.2018.10.001_bib0089","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","article-title":"Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study","volume":"8","author":"Nilsson","year":"2007","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.10.001_bib0090","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eururo.2012.09.008","article-title":"A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer","volume":"63","author":"Parker","year":"2013","journal-title":"Eur Urol"},{"issue":"12","key":"10.1053\/j.seminoncol.2018.10.001_bib0091","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","article-title":"Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPC","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2018.10.001_bib0092","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.10.001_bib0093","doi-asserted-by":"crossref","first-page":"S477","DOI":"10.1016\/S0959-8049(15)30047-2","article-title":"2510 3-year follow-up of chemotherapy following radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients (Pts) with symptomatic bone metastases (Mets) from ALSYMPCA","volume":"51","author":"Sartor","year":"2015","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.10.001_bib0094","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s00120-016-0030-8","article-title":"[Advanced Prostate Cancer Consensus Conference (APCCC) 2015 in St. Gallen: critical review of the recommendations on diagnosis and therapy of metastatic prostate cancer by a German expert panel]","volume":"55","author":"Thomas","year":"2016","journal-title":"Urologe A"},{"key":"10.1053\/j.seminoncol.2018.10.001_bib0095","series-title":"ESMO [Internet]","article-title":"765PD\u2014safety of Radium-223 dichloride with docetaxel in patients with bone metastases from castration-resistant prostate cancer: a phase 1\/2a clinical trial","author":"Morris","year":"2014"},{"issue":"3","key":"10.1053\/j.seminoncol.2018.10.001_bib0096","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2011.11.009","article-title":"Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer","volume":"61","author":"Armstrong","year":"2012","journal-title":"Eur Urol"},{"issue":"25","key":"10.1053\/j.seminoncol.2018.10.001_bib0097","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1200\/JCO.2005.08.156","volume":"23","author":"Collette","year":"2005","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1053\/j.seminoncol.2018.10.001_bib0098","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2013.50.3201","article-title":"Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy","volume":"31","author":"Halabi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminoncol.2018.10.001_bib0099","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/jjco\/hyu148","article-title":"A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy","volume":"44","author":"Satoh","year":"2014","journal-title":"Jpn J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminoncol.2018.10.001_bib0100","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/jjco\/hyu149","article-title":"A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study)","volume":"44","author":"Matsubara","year":"2014","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.10.001_bib0101","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12894-016-0148-4","article-title":"Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials","volume":"16","author":"Nakayama","year":"2016","journal-title":"BMC Urol"},{"issue":"7","key":"10.1053\/j.seminoncol.2018.10.001_bib0102","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/1078-0432.CCR-14-1961","article-title":"Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate","volume":"21","author":"Attard","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1053\/j.seminoncol.2018.10.001_bib0103","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17071097","article-title":"Common genetic variation in CYP17A1 and response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer","volume":"17","author":"Binder","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.10.001_bib0104","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.eururo.2016.05.023","article-title":"Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer","volume":"70","author":"Lorente","year":"2016","journal-title":"Eur Urol"},{"issue":"7","key":"10.1053\/j.seminoncol.2018.10.001_bib0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158952","article-title":"Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer","volume":"11","author":"Conteduca","year":"2016","journal-title":"PLoS One"},{"issue":"23","key":"10.1053\/j.seminoncol.2018.10.001_bib0106","doi-asserted-by":"crossref","first-page":"12448","DOI":"10.18632\/oncotarget.2558","article-title":"Early outcome prediction on 18F-fluorocholine PET\/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone","volume":"5","author":"De Giorgi","year":"2014","journal-title":"Oncotarget"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775417300507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775417300507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:54:31Z","timestamp":1758804871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775417300507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":106,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0093775417300507"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2018.10.001","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current therapeutic options in metastatic castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2018.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}